Eubiologics, the South Korean vaccine manufacturer and joint venture partner of Filipino pharmaceutical Glovax Biotech Corp., is targeting to start clinical trial in the country this month for its EuCorVac-19 Covid vaccine. 

Photo credit:

Glovax Philippines President and CEO Giovanni Alingog showed a letter by Secretary Carlito G. Galvez, Jr., the Chief Implementer and Vaccine Czar of the National Task Force Against Covid-19 to the Department of Science and Technology for a possible tripartite agreement, after its review and recommendation on the EuCorVac-19 Covid Vaccine by its Vaccine Panel Expert headed by Dr. Nina Gloriani.

Following the endorsement, Alingog said Glovax is already in talks with the DOST and DOH for the inclusion of EuCorVac-19 Covid Vaccine in our local clinical trials and other publication such as the Resbakuna Program headed by Undersecretary of Health Dr. Myrna C. Cabotaje.

Alingog said that clinical trial normally takes a year, but he was looking at completing the trial in July as processes are being fast tracked due to the pandemic. 

“The EuCorVac-19 Covid Vaccine clinical trial will be first of its kind in the Philippines for a Covid Vaccine as it will be a platform-to-platform comparison,” said Alingog. This platform to platform comparison means that the EuBiologics technology and the way their Covid Vaccine was made will be compared with other manufacturers for efficacy, immunogenicity, and safety. 

“As you know, there are already many different types of Covid Vaccine such as mRNA, DNA, inactivated, split, and protein sub-unit, among others. EuCorVac-19 is a nano-particle protein sub-unit vaccine which is similar to Novovax. Not all Covid vaccines that will be available has a clinical trial in the Philippines and none has a platform-to-platform comparison done here,” he said.

EuCorVac-19 was already approved for Phase 1 and Phase 2 clinical trials in Korea and Glovax will soon apply for the Emergency Use Authorization (EUA). The same technology will be used by Glovax for the production of the Covid Vaccine locally just like Serum Institute of India (SII) will be producing in India their Covovax version of the Novovax. A separate clinical trial will be required for different manufacturers even if it is the same vaccines that are already approved. Glovax intends to have its clinical trials to be made locally.

Glovax Philippines President and CEO Giovanni Alingog

EuCorVac-19 was developed in the US and will be manufactured in Korea by EuBiologics and eventually in the Philippines through its joint venture partner Glovax. 

Glovax earlier already announced that it will be putting up the Covid Vaccine Plant with a tech transfer from EuBiologics. EuBiologics already has reserved 40 million doses for the Philippines as a sign of Korean friendship prioritizing us over other countries.

Glovax is also in talks with MVP for a possible collaboration with his group. The talks started in 2020 and MVP sees a lot of synergies between Glovax and his companies like PayMaya, SMART, Meralco and MPIC Hospitals. Glovax also intends to supply these private companies of the Covid Vaccine because now the government is already allowing private sectors to get their own supply to help the government in fighting the Covid-19 pandemic. 

Meantime, Alingog said hat Glovax will make available the EuCorVac-19 Covid Vaccines in all its Vaxcen Bakuna Center, which was already approved by SM Malls. Vaxcen Bakuna Center is the first of its kind because it caters only for healthy adults and well-babies for vaccination unlike if you will have your vaccination in health centers or hospitals where other people with diseases go. There is a less chance or risk of getting diseases at any Vaxcen Bakuna Center. 

The Vaxcen Bakuna Center will be located in all 76 SM Malls nationwide starting with Megamall, The Block North Edsa, MOA, and Clark. Eventually, it will be rolled out this year in all SM Malls. Vaxcen Bakuna Center caters to all available vaccines such as Influenza, Pneumonia and Rabies vaccines all year round.

Glovax is also in talks with the Department of Trade and Industry (DTI) for a possible collaboration in offering the Covid vaccine to private companies including its vaccination monitoring service called Vaxcen Passport®. Glovax is among the firms mentioned by the DTI as already in the advanced stage for their proposal to build a vaccine manufacturing plant in the country. 

Source: Manila Bulletin (